UNICHEMLABUnichem Laboratories Ltd.
Unichem Laboratories Q2 FY27 Results: Consolidated Net Profit ₹22.22 Crore on Total Income of ₹656 Crore
- Earnings
- pharmaceuticals
Reviewed byRachit TripathiBlacklitt Research
Unichem Laboratories (NSE: UNICHEMLAB) reported consolidated total income of ₹655.59 crore and a net profit of ₹22.22 crore for the quarter ended 30 Sep 2026, and standalone total income of ₹418.75 crore with a net profit of ₹1.49 crore, it said in a filing on 04 Nov 2026. The figures are unaudited and the auditors gave an unmodified conclusion.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹655.59 crore, up 9.3% YoY and 1.1% QoQ
- Net profit and EPS: ₹22.22 crore against a loss of ₹11.89 crore a year earlier; basic EPS ₹3.16
- Exceptional items: ₹24.26 crore provision for a claim in subsidiary Niche Generics Limited
- Finance costs: ₹7.71 crore, down 6.4% YoY and up 16.5% QoQ
Standalone
The company on its own, without its subsidiaries
- Total income: ₹418.75 crore, up 10.7% YoY and 9.3% QoQ
- Net profit and EPS: ₹1.49 crore against a loss of ₹39.93 crore a year earlier; basic EPS ₹0.21
- Exceptional items: Nil in the quarter, against a net ₹33.14 crore expense a year earlier
- Finance costs: ₹1.77 crore, down 51.9% YoY and up 37.2% QoQ
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 655.59 | 599.93 | +9.3% | 648.23 | +1.1% | |
| Revenue from operations | 640.22 | 578.96 | +10.6% | 632.62 | +1.2% |
| Other income | 15.37 | 20.97 | -26.7% | 15.61 | -1.5% |
| 22.22 | -11.89 | n/a | 41.47 | -46.4% | |
| Profit before tax | 27.37 | -10.82 | n/a | 48.99 | -44.1% |
| Finance costs | 7.71 | 8.24 | -6.4% | 6.62 | +16.5% |
| Depreciation | 30.49 | 31.47 | -3.1% | 29.94 | +1.8% |
| Tax expense | 5.15 | 1.07 | +381.3% | 7.52 | -31.5% |
| Net profit margin | 3.39% | -1.98% | +5.37 pp | 6.40% | -3.01 pp |
| EPS, basic (₹) | 3.16 | -1.69 | n/a | 5.89 | -46.3% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Consolidated net profit moved far more than total income. Total income rose 9.3% from a year earlier, but the year-earlier quarter carried a pre-tax loss of ₹10.82 crore after a ₹58.26 crore exceptional expense for interest on the European Commission fine. Against the quarter before, net profit fell 46.4% while total income rose 1.1%.
Other income fell 26.7% from a year earlier, while revenue from operations rose 10.6%. The filing does not say why other income fell.
The quarter includes a ₹24.26 crore exceptional expense. The notes say it is a provision for a claim by Laboratories Servier over UK Perindopril proceedings, recognised in the books of Niche Generics Limited and stated as £1.9 million. Niche Generics Limited intends to resolve the matter by compromise if possible. Tax expense of ₹5.15 crore is 18.8% of pre-tax profit; the company says there is no current tax charge for the quarter because of the set-off of unabsorbed tax depreciation and business loss, and deferred tax has been recorded.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 418.75 | 378.30 | +10.7% | 382.99 | +9.3% | |
| Revenue from operations | 401.90 | 356.90 | +12.6% | 366.27 | +9.7% |
| Other income | 16.85 | 21.40 | -21.3% | 16.72 | +0.8% |
| 1.49 | -39.93 | n/a | 5.53 | -73.1% | |
| Profit before tax | 2.03 | -37.83 | n/a | 7.38 | -72.5% |
| Finance costs | 1.77 | 3.68 | -51.9% | 1.29 | +37.2% |
| Depreciation | 28.98 | 30.11 | -3.8% | 28.69 | +1.0% |
| Tax expense | 0.54 | 2.10 | -74.3% | 1.85 | -70.8% |
| Net profit margin | 0.36% | -10.56% | +10.91 pp | 1.44% | -1.09 pp |
| EPS, basic (₹) | 0.21 | -5.67 | n/a | 0.79 | -73.4% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone net profit of ₹1.49 crore is much smaller than the consolidated figure of ₹22.22 crore, a gap of ₹20.73 crore. Standalone total income rose 10.7% YoY and 9.3% QoQ, faster than consolidated total income on both measures.
Standalone tax expense of ₹0.54 crore is 26.6% of profit before tax, and the company says no current tax is charged for the quarter.
In the half year to 30 Sep 2026, the standalone company invested USD 80,000, about ₹0.76 crore, in redeemable preference shares of its wholly owned subsidiary Unichem (China) Pvt Ltd.
The company operates a single reportable segment, Pharmaceuticals. The auditors reviewed both sets of results and expressed unmodified conclusions. For the subsidiaries in the USA and Niche Generics Limited, the auditors relied on the review of other auditors, and for other subsidiaries they relied on management information which they describe as not material to the group.
Inference
The filing reports the Board's approval of the results on 4 Nov 2026 and the auditors' unmodified conclusion. The filing does not say whether the Servier claim will be settled, when, or for what amount beyond the provision, and it does not say whether any part of the EU fine or the Servier provision will be recovered.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
